NEWS
FSD Pharma strikes deal with Solarvest BioEnergy to develop pharmaceutical-grade cannabinoids from algae
| Proactive Investors

FSD Pharma Inc (CSE:HUGE) announced Tuesday it has entered into an agreement with Solarvest BioEnergy Inc (TSV:SVS) to develop pharmaceutical-grade cannabinoids from algae. Solarvest, based in Vancouver, British Columbia, employs a production platform capable of producing health products from algae. Under the agreement, Solarvest will carry out a CBD research project to determine if its algal expression system […]

Vericel looks to market a gel for burns with new $142M licensing deal
| Boston Business Journal

Cambridge-based cell therapy firm Vericel Corp. has forged a $142 million deal to license a gel used to help heal burns that made just over $3 million in sales last year at an Israeli company. Vericel (Nasdaq: VCEL) will pay $17.5 million upfront and up to $125 million in milestones to license and sell the burn repair product NexoBrid […]

New Experimental Therapy CAR NKT-Cells Tested In Cancer Patients For The First Time
| Forbes

CAR T-cells are becoming somewhat of a household name, but a new phase I trial is, for the first time, using CAR ‘NKT’ cells, featuring genetic modification of a different immune cell, natural killer cells. Natural killer T-cells have long been known to be important in mediating the immune system’s response to cancer, targeting both tumor cells […]